Igf::ot::igf Development and Evaluation of the Hepaplate Ips: a High Throughput Organ on a Chip Ips Hepatotoxicty Screening Platform

Period of Performance: 05/15/2016 - 05/14/2017

$225K

Phase 1 SBIR

Recipient Firm

Mimetas US, Inc.
ROCKVILLE, MD 20850
Principal Investigator

Abstract

This is an SBIR Phase I contract focused on improving the testing of hepatoxicity through the development of the organoplate.